Misplaced Pages

Medetomidine/vatinoxan

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Vatinoxan) Medication

Pharmaceutical compound
Medetomidine/vatinoxan
Chemical structures of medetomidine (top) and vatinoxan
Combination of
Medetomidinealpha2-adrenoceptor agonist
Vatinoxanalpha2-adrenoceptor antagonist
Clinical data
Trade namesZenalpha
License data
Routes of
administration		Intramuscular
ATC code
  • None
Legal status
Legal status

Medetomidine/vatinoxan, sold under the brand name Zenalpha, is a veterinary fixed dose combination medication used as a sedative and analgesic for dogs. It contains medetomidine, an alpha2-adrenoceptor agonist, as the hydrochloride; and vatinoxan, an alpha2-adrenoceptor antagonist, as the hydrochloride.

It was approved for veterinary use in the United States in May 2022, and in Canada in May 2023.

References

  1. ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-06-23]". Health Canada. 23 June 2023. Retrieved 3 March 2024.
  2. ^ "Zenalpha- vatinoxan hydrochloride and medetomidine hydrochloride solution". DailyMed. 11 May 2022. Retrieved 3 March 2024.
  3. "Zenalpha – Label" (PDF). Dechra Veterinary Products Inc. Government of Canada. 20 March 2023.
Portal:


Stub icon

This veterinary medicine–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: